$VTYX
Ventyx Biosciences, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023021286 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.585M $7.115M $5.338M
YoY Change 50.03% 33.29%
% of Gross Profit
Research & Development $48.56M $35.44M $17.41M
YoY Change 230.88% 103.56% -29.23%
% of Gross Profit
Depreciation & Amortization $34.00K $31.00K $21.00K
YoY Change 41.67% 47.62% 2000.0%
% of Gross Profit
Operating Expenses $57.15M $42.55M $22.75M
YoY Change 180.15% 87.07% -10.26%
Operating Profit -$57.15M -$42.55M -$22.75M
YoY Change 180.15% 87.07% -10.26%
Interest Expense $3.899M $3.622M $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $3.894M $3.621M $15.00K
YoY Change 924.74% 24040.0% -100.12%
Pretax Income -$53.25M -$38.93M -$22.73M
YoY Change 166.02% 71.26%
Income Tax
% Of Pretax Income
Net Earnings -$53.25M -$38.93M -$22.73M
YoY Change 166.02% 71.26% -39.61%
Net Earnings / Revenue
Basic Earnings Per Share -$0.91 -$0.68 -$0.45
Diluted Earnings Per Share -$0.91 -$0.68 -$449.4K
COMMON SHARES
Basic Shares Outstanding 58.56M 58.21M 50.73M
Diluted Shares Outstanding 58.56M 57.64M 50.59M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $332.3M $376.9M $254.3M
YoY Change 32.66% 48.19%
Cash & Equivalents $51.72M $63.67M $41.69M
Short-Term Investments $280.5M $313.2M $212.7M
Other Short-Term Assets $14.45M $10.14M $3.159M
YoY Change 729.93% 220.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $346.7M $387.1M $257.5M
YoY Change 37.47% 50.31%
LONG-TERM ASSETS
Property, Plant & Equipment $629.0K $586.0K $275.0K
YoY Change 119.16% 113.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $18.80M
YoY Change -100.0% -100.0%
Other Assets $102.0K $96.00K $60.00K
YoY Change 41.67% 60.0%
Total Long-Term Assets $2.062M $2.118M $20.45M
YoY Change -79.36% -89.64%
TOTAL ASSETS
Total Short-Term Assets $346.7M $387.1M $257.5M
Total Long-Term Assets $2.062M $2.118M $20.45M
Total Assets $348.8M $389.2M $278.0M
YoY Change 33.02% 40.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.085M $6.552M $7.114M
YoY Change -29.63% -7.9%
Accrued Expenses $15.51M $9.537M $10.40M
YoY Change 35.07% -8.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.03M $16.52M $17.79M
YoY Change 13.35% -7.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $922.0K $1.036M $1.039M
YoY Change -32.16% -0.29%
Total Long-Term Liabilities $922.0K $1.036M $1.039M
YoY Change -32.16% -0.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.03M $16.52M $17.79M
Total Long-Term Liabilities $922.0K $1.036M $1.039M
Total Liabilities $20.96M $17.55M $18.83M
YoY Change 10.1% -6.79%
SHAREHOLDERS EQUITY
Retained Earnings -$318.4M -$265.2M -$140.5M
YoY Change 98.32% 88.68%
Common Stock $6.000K $6.000K $5.000K
YoY Change 20.0% 20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $327.8M $371.6M $259.1M
YoY Change
Total Liabilities & Shareholders Equity $348.8M $389.2M $278.0M
YoY Change 33.02% 40.01%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$53.25M -$38.93M -$22.73M
YoY Change 166.02% 71.26% -39.61%
Depreciation, Depletion And Amortization $34.00K $31.00K $21.00K
YoY Change 41.67% 47.62% 2000.0%
Cash From Operating Activities -$49.28M -$30.92M -$12.73M
YoY Change 233.17% 142.98% 321.53%
INVESTING ACTIVITIES
Capital Expenditures $195.0K $60.00K $38.00K
YoY Change -796.43% 57.89%
Acquisitions
YoY Change
Other Investing Activities $35.01M -$18.84M -$16.47M
YoY Change 91.56% 14.39%
Cash From Investing Activities $34.82M -$18.90M -$16.50M
YoY Change 90.79% 14.49% -969.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.473M 48.65M 86.00K
YoY Change 893.17% 56465.12% -99.85%
NET CHANGE
Cash From Operating Activities -49.28M -30.92M -12.73M
Cash From Investing Activities 34.82M -18.90M -16.50M
Cash From Financing Activities 2.473M 48.65M 86.00K
Net Change In Cash -11.99M -1.150M -29.10M
YoY Change -423.44% -96.05% -152.2%
FREE CASH FLOW
Cash From Operating Activities -$49.28M -$30.92M -$12.73M
Capital Expenditures $195.0K $60.00K $38.00K
Free Cash Flow -$49.48M -$30.98M -$12.76M
YoY Change 235.12% 142.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssets
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssets
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001851194
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-40928
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Ventyx Biosciences, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2996852
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
662 Encinitas Blvd
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Encinitas
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92024
CY2023Q1 dei City Area Code
CityAreaCode
760
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
593-4832
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
VTYX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58556952
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63669000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64819000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
313246000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
253122000
CY2023Q1 vtyx Prepaid Expense And Other Assets Related Party
PrepaidExpenseAndOtherAssetsRelatedParty
49000
CY2022Q4 vtyx Prepaid Expense And Other Assets Related Party
PrepaidExpenseAndOtherAssetsRelatedParty
47000
CY2023Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
10136000
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
12747000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
387051000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
330688000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
586000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
407000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1436000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1537000
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
38672000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
96000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
96000
CY2023Q1 us-gaap Assets
Assets
389169000
CY2022Q4 us-gaap Assets
Assets
371400000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6552000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6433000
CY2023Q1 vtyx Accrued Expenses Related Party
AccruedExpensesRelatedParty
240000
CY2022Q4 vtyx Accrued Expenses Related Party
AccruedExpensesRelatedParty
64000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9537000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9514000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
426000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
412000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16515000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16359000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1036000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1146000
CY2023Q1 us-gaap Liabilities
Liabilities
17551000
CY2022Q4 us-gaap Liabilities
Liabilities
17505000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58385787
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57025847
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58348727
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56980845
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
637329000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
581237000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-561000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1123000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-265156000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-226225000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
371618000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
353895000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
389169000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
371400000
CY2023Q1 vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
250000
CY2022Q1 vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
203000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35437000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17409000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7115000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5338000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
42552000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
22747000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-42552000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22747000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
3622000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
132000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-117000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3621000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-38931000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-22732000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
539000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-942000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
23000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
42000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38369000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23632000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57638923
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57638923
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50585255
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50585255
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
353895000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1117000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6567000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
539000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
23000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-38931000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
371618000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
279199000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
86000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
26000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3444000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-942000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
42000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-22732000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
259123000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-38931000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-22732000
CY2023Q1 us-gaap Depreciation
Depreciation
31000
CY2022Q1 us-gaap Depreciation
Depreciation
21000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
103000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
69000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6567000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3444000
CY2023Q1 vtyx Accretion Of Marketable Securities
AccretionOfMarketableSecurities
-2078000
CY2023Q1 vtyx Increase Decrease In Prepaid Expense And Other Assets Related Party Amounts
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsRelatedPartyAmounts
-2000
CY2022Q1 vtyx Increase Decrease In Prepaid Expense And Other Assets Related Party Amounts
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsRelatedPartyAmounts
-5000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3758000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5099000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-97000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-64000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
0
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
305000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-91000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1782000
CY2023Q1 vtyx Increase Decrease In Accrued Liabilities Related Party Amounts
IncreaseDecreaseInAccruedLiabilitiesRelatedPartyAmounts
176000
CY2022Q1 vtyx Increase Decrease In Accrued Liabilities Related Party Amounts
IncreaseDecreaseInAccruedLiabilitiesRelatedPartyAmounts
-101000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-183000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3219000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30921000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12726000
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
108835000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
68675000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
90000000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
52210000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
60000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
38000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18895000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16503000
CY2023Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
48455000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
216000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
86000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
25000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48646000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
86000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1150000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29101000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64819000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70791000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63669000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41690000
CY2023Q1 vtyx Exercise Of Stock Options
ExerciseOfStockOptions
1043000
CY2023Q1 us-gaap Noncash Or Part Noncash Acquisition Inventory Acquired1
NoncashOrPartNoncashAcquisitionInventoryAcquired1
149000
CY2023Q1 vtyx Deferred Offering Costs Unpaid
DeferredOfferingCostsUnpaid
78000
CY2023Q1 vtyx Unpaid Costs Associated With The Issuance Of Common Stock Under The At The Market Sales Agreement
UnpaidCostsAssociatedWithTheIssuanceOfCommonStockUnderTheAtTheMarketSalesAgreement
46000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
407000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M26D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
159929000
CY2023Q1 vtyx Number Of Acquired Wholly Owned Subsidiaries
NumberOfAcquiredWhollyOwnedSubsidiaries
2
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
313799000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
45000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
598000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
313246000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
292886000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
20000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1112000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
291794000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
33
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
33
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
29
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
4
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
37
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
37
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
32
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
5
CY2023Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
CY2023Q1 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
1000000.0
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
900000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
714000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
502000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
128000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
95000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
586000
CY2023Q1 vtyx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3746000
CY2022Q4 vtyx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
2450000
CY2023Q1 vtyx Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
2580000
CY2022Q4 vtyx Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1235000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2252000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4208000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
719000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1557000
CY2023Q1 vtyx Accrued Related Party Liabilities Current
AccruedRelatedPartyLiabilitiesCurrent
240000
CY2022Q4 vtyx Accrued Related Party Liabilities Current
AccruedRelatedPartyLiabilitiesCurrent
64000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9537000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9514000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of outstanding shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13121734
CY2021Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-06-30
CY2021Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-06-30
CY2021Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-06-30
CY2023Q1 us-gaap Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
The leases contain various termination options.
CY2023Q1 us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1436000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1537000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
426000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
412000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1036000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1146000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1462000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1558000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
401000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
517000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
503000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
255000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1676000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
214000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1462000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
426000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1036000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6567000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3444000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6567000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3444000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7592856
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.82
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1776554
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
34.73
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
183470
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.09
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
383232
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
24.09
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8802708
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.94
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
156884000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8802708
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
15.94
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y9M
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
156884000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2871829
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.63
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y11M26D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
74312000
CY2023Q1 vtyx Number Of Employees Terminated
NumberOfEmployeesTerminated
1
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-38931000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-22732000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57638923
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57638923
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50585255
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50585255
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9614464
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7894945

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-021286-index-headers.html Edgar Link pending
0000950170-23-021286-index.html Edgar Link pending
0000950170-23-021286.txt Edgar Link pending
0000950170-23-021286-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtyx-20230331.htm Edgar Link pending
vtyx-20230331.xsd Edgar Link pending
vtyx-ex10_1.htm Edgar Link pending
vtyx-ex31_1.htm Edgar Link pending
vtyx-ex31_2.htm Edgar Link pending
vtyx-ex32_1.htm Edgar Link pending
vtyx-ex32_2.htm Edgar Link pending
vtyx-20230331_def.xml Edgar Link unprocessable
vtyx-20230331_lab.xml Edgar Link unprocessable
vtyx-20230331_cal.xml Edgar Link unprocessable
vtyx-20230331_pre.xml Edgar Link unprocessable
vtyx-20230331_htm.xml Edgar Link completed